Prognosis and Course of COVID-19 Infection in Hospitalised Patients
NCT ID: NCT04752085
Last Updated: 2023-01-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
345 participants
OBSERVATIONAL
2020-11-01
2023-01-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators plan to include 300 patients hospitalised with COVID-19 infection.
The phone contacts with patients are due after 90 and 180 days after discharge.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optimization of Patients Long-term Management After the Coronavirus Infection COVID-19
NCT04871789
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study
NCT04365764
Comorbidities and Risk Score in COVID-19 Patients
NCT04670094
Clinical, Virological, Serological and Immunological Characteristics During and Following COVID-19 Hospitalization
NCT05274373
Long-term Follow-up Study of COVID-19
NCT05986435
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Chitotriosidase activity
The chitotriosidase activity will be measured in all the subjects
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Discharge from the hospital before the end of the treatment course
* Transfer to another hospital
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
I.M. Sechenov First Moscow State Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Olga Mironova
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Olga Mironova, PhD
Role: PRINCIPAL_INVESTIGATOR
Sechenov University
Ekaterina Schelkanovtseva, MD
Role: STUDY_CHAIR
Sechenov University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital #1
Moscow, , Russia
University Hospital #4
Moscow, , Russia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Schelkanovtseva ES, Isaev GO, Mironova OY, Balakhonov AA, Skvortsov AV, Nagornov IO, Suvorov AY, Fomin VV, Panferov AS. [The survival prediction of hospitalized patients with COVID-19: the role of chitotriosidase level in peripheral blood]. Ter Arkh. 2023 Sep 29;95(7):543-547. doi: 10.26442/00403660.2023.07.202280. Russian.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
03-21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.